Lassen Therapeutics
Lassen Therapeutics is a biotech company dedicated to developing innovative antibody therapeutics for fibrosis, rare diseases, and oncology. Their mission is to create transformational medicines by combining innovative science, leading technology, and unmatched know-how. They focus on targeting the IL-11 pathway, a central mediator of fibrosis, with the goal of improving patient outcomes in serious diseases.
Industries
Nr. of Employees
small (1-50)
Lassen Therapeutics
5510 Morehouse Drive, Suite 100, San Diego, CA 92121
Patents
Method of treating an interleukin-11-associated or -mediated fibrotic disease or condition by administering an anti-interleukin-11 receptor subunit alpha (IL-11RA) antibody
US-12365738-B2
View Details
Method of treating an interleukin-11-associated or -mediated fibrotic disease or condition by administering an anti-interleukin-11 receptor subunit alpha (IL-11RA) antibody
US-12365738-B2
View DetailsProducts
LASN01
A monoclonal antibody targeting the IL-11 receptor, aimed at treating fibro-inflammatory diseases such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).
LASN500
A monoclonal antibody targeting the IL-18 binding protein (IL-18BP), intended for cancer treatment by elevating IL-18 at the tumor site.
LASN01
A monoclonal antibody targeting the IL-11 receptor, aimed at treating fibro-inflammatory diseases such as thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).
LASN500
A monoclonal antibody targeting the IL-18 binding protein (IL-18BP), intended for cancer treatment by elevating IL-18 at the tumor site.
News & Updates
Proceeds will fund Phase 2 study in thyroid eye disease (TED) with LASN01 and continue development of LASN500 in Investigational New Drug (IND) enabling studies.
Blockade of the IL-11 pathway with LASN01 offers a potential new therapeutic option for thyroid eye disease.
LASN01, a fully human, clinical-stage antibody which binds to IL-11R, potently blocks IL-11 signaling to prevent IL-11 driven fibrotic diseases.
Inhibition of signaling through IL-11R with LASN01 offers a potential novel treatment for idiopathic pulmonary fibrosis and other fibro-inflammatory diseases.
Lassen to also be featured at the ATS Respiratory Innovation Summit.
Industry veteran Dr. Fardis to succeed current CEO Mark Barrett to lead Lassen in its next phase of growth and ongoing advancement of clinical programs.
Proceeds will fund Phase 2 study in thyroid eye disease (TED) with LASN01 and continue development of LASN500 in Investigational New Drug (IND) enabling studies.
Blockade of the IL-11 pathway with LASN01 offers a potential new therapeutic option for thyroid eye disease.
LASN01, a fully human, clinical-stage antibody which binds to IL-11R, potently blocks IL-11 signaling to prevent IL-11 driven fibrotic diseases.
Inhibition of signaling through IL-11R with LASN01 offers a potential novel treatment for idiopathic pulmonary fibrosis and other fibro-inflammatory diseases.
Lassen to also be featured at the ATS Respiratory Innovation Summit.
Industry veteran Dr. Fardis to succeed current CEO Mark Barrett to lead Lassen in its next phase of growth and ongoing advancement of clinical programs.